ReviewClinical immunology (Orlando, Fla.)2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Review in Clinical immunology (Orlando, Fla.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 714 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Nutritional Habits, Does it Affect Coronavirus Disease 2019 (COVID-19) Infection Outcome? An Egyptian Experience
Comparison of Cytokine Hemadsorption as an Immunomodulator Therapy in Covid 19 Patients With and Without Bacterial Sepsis
Evaluation of Independent Clinical- Laboratory Predictors of Clinical Outcomes in Hospitalized Positive SARS-CoV2 Patients (Outcomes SARS-CoV2)
Who cites it
714 citing papers in PubMed, 10 syntheses or guidelines pooled it, 1,306 citations in OpenAlex.
- Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19.Endocrine · 2024Pooled it
- Effectiveness of corticosteroids to treat coronavirus disease 2019 symptoms: A meta-analysis.Medicina clinica · 2022Pooled it
- Pulse versus nonpulse steroid regimens in patients with coronavirus disease 2019: A systematic review and meta-analysis.Journal of medical virology · 2022Pooled it
- COVID-19 and New Onset IgA Vasculitis: A Systematic Review of Case Reports.Journal of emergency nursing · 2022Pooled it
- Pooled it
- Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis.Expert review of anti-infective therapy · 2022Pooled it
- Medical image processing and COVID-19: A literature review and bibliometric analysis.Journal of infection and public health · 2022Pooled it
- Systemic inflammation in COVID-19 patients may induce various types of venous and arterial thrombosis: A systematic review.Scandinavian journal of immunology · 2021Pooled it
- Lipid profile as an indicator of COVID-19 severity: A systematic review and meta-analysis.Clinical nutrition ESPEN · 2021Pooled it
- Efficacy and safety of hyperbaric oxygen treatment in SARS-COV-2 (COVID-19) pneumonia: a systematic review.Diving and hyperbaric medicine · 2021Pooled it
- Methylprednisolone pulse therapy compared with intravenous dexamethasone for severe COVID-19 patients: a randomized clinical trial.Virology journal · 2025Trial
- Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Effect of ArtemiC in patients with COVID-19: A Phase II prospective study.Journal of cellular and molecular medicine · 2022Trial
- Vasculitis syndromes: the pathogenic roles of COVID-19 and related vaccinations.Virology journal · 2025Review
- Reduction of extracellular vimentin in blood provides protection against SARS-CoV-2 infection.Virulence · 2025Article
- Functional and genomic evaluation of novel exopolysaccharide produced by marine Pediococcus pentosaceus E3 with antidiabetic, anticancer, and anti-inflammatory potentials.BMC microbiology · 2025Article
- Metabolomic Approach to Identify the Potential Metabolites from Alpinia malaccensis for Treating SARS-CoV-2 Infection.Biochemical genetics · 2025Article
- The Antiviral Efficacy and Safety of Azvudine in Hospitalized SARS-CoV-2 Infected Patients with Liver Diseases Based on a Multicenter, Retrospective Cohort Study.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Observational
- Bridging Cancer and COVID-19: The Complex Interplay of ACE2 and TMPRSS2.Cancer medicine · 2025Review
- Religiosity and Health Outcomes in a Cohort of Romanian Patients Hospitalized for COVID-19.Journal of religion and health · 2025Observational
654 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pandemic outbreak of coronavirus disease 2019 (COVID-19) is rapidly spreading all over the world. Reports from China showed that about 20% of patients developed severe disease, resulting in a fatality of 4%. In the past two months, we clinical immunologists participated in multi-rounds of MDT (multidiscipline team) discussion on the anti-inflammation management of critical COVID-19 patients, with our colleagues dispatched from Chinese leading PUMC Hospital to Wuhan to admit and treat the most severe patients. Here, from the perspective of clinical immunologists, we will discuss the clinical and immunological characteristics of severe patients, and summarize the current evidence and share our experience in anti-inflammation treatment, including glucocorticoids, IL-6 antagonist, JAK inhibitors and choloroquine/hydrocholoroquine, of patients with severe COVID-19 that may have an impaired immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.